Portolan Capital Management LLC Purchases 1,407,818 Shares of Cellebrite DI Ltd. $CLBT

Portolan Capital Management LLC raised its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 139.1% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 2,419,662 shares of the company’s stock after buying an additional 1,407,818 shares during the period. Cellebrite DI makes up about 2.4% of Portolan Capital Management LLC’s portfolio, making the stock its 10th biggest holding. Portolan Capital Management LLC’s holdings in Cellebrite DI were worth $44,836,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of CLBT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Cellebrite DI by 16.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company’s stock valued at $3,362,000 after buying an additional 24,881 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Cellebrite DI by 11.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,287,954 shares of the company’s stock worth $20,607,000 after acquiring an additional 133,651 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in Cellebrite DI by 1,998.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock valued at $34,000 after acquiring an additional 1,998 shares during the period. Geode Capital Management LLC boosted its holdings in Cellebrite DI by 16.2% during the 2nd quarter. Geode Capital Management LLC now owns 314,440 shares of the company’s stock valued at $5,029,000 after acquiring an additional 43,898 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey grew its position in Cellebrite DI by 9.8% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 23,633 shares of the company’s stock valued at $378,000 after acquiring an additional 2,101 shares in the last quarter. 45.88% of the stock is owned by institutional investors and hedge funds.

Cellebrite DI Trading Down 0.6%

NASDAQ:CLBT opened at $14.44 on Friday. The firm has a market cap of $3.60 billion, a PE ratio of 46.58, a price-to-earnings-growth ratio of 2.23 and a beta of 1.30. The stock has a fifty day moving average price of $15.27 and a 200 day moving average price of $16.90. Cellebrite DI Ltd. has a 12-month low of $11.76 and a 12-month high of $20.86.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, hitting the consensus estimate of $0.14. The company had revenue of $128.82 million for the quarter, compared to the consensus estimate of $126.07 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.Cellebrite DI’s revenue was up 28.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.10 EPS. Equities analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on CLBT. Needham & Company LLC cut their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 29th. Finally, Wall Street Zen cut shares of Cellebrite DI from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.